Chinese biotechnology start-up Juventas announced on Tuesday that it has raised RMB100 million (US$14.51 million) in a series A+ round of financing led by Nasdaq-listed pharmaceutical firm CASI Pharmaceuticals. The company’s returning investor Dalton Venture and Panacea Venture, a China-based venture capital firm backed by former partners of Kleiner Perkins Caufield & Byers China (KPCB […]

Chinese Biotech Start-Up Juventas Gets $14M In Series A+ Round comes originally from China Money Network. All Rights Reserved.